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Abstract
Background: Reactive oxygen species generated by hyperglycaemia modify structure and function
of lipids, proteins and other molecules taking part in chronic vascular changes in diabetes mellitus
(DM). Low activity of scavenger enzymes has been observed in patients with DM. Protective role
of scavenger enzymes may be deteriorated by oxidative stress. This study was undertaken to
investigate the association between gene polymorphisms of selected antioxidant enzymes and
vascular complications of DM.
Results:  Significant differences in allele and genotype distribution among T1DM, T2DM and
control persons were found in SOD1 and SOD2 genes but not in CAT gene (p < 0,01). Serum SOD
activity was significantly decreased in T1DM and T2DM subjects compared to the control subjects
(p < 0,05). SOD1 and SOD2 polymorphisms may affect SOD activity. Serum SOD activity was
higher in CC than in TT genotype of SOD2 gene (p < 0,05) and higher in AA than in CC genotype
of SOD1 gene (p < 0,05). Better diabetes control was found in patients with CC than with TT
genotype of SOD2 gene. Significantly different allele and genotype frequencies of SOD2 gene
polymorphism were found among diabetic patients with macroangiopathy and those without it. No
difference was associated with microangiopathy in all studied genes.
Conclusion: The results of our study demonstrate that oxidative stress in DM can be accelerated
not only due to increased production of ROS caused by hyperglycaemia but also by reduced ability
of antioxidant defense system caused at least partly by SNPs of some scavenger enzymes.
Background
It is a well-estabilished fact that diabetes mellitus is a risk
factor for cardiovascular disease [1] which is leading cause
of death in diabetic population [2]. It is also well-known
fact that tight control of diabetes is effective in reducing
vascular complications [3]. One of the principal pathways
to develop vascular complications is the production of
ROS [4]. There are multiple sources of oxidative stress in
diabetes including nonenzymatic and enzymatic path-
ways [5]. While ROS are generated under physiological
conditions [6], excess generation of ROS has pathological
consequences [7]. ROS can stimulate oxidation of LDL,
forming ox-LDL, which is not recognized by the LDL
receptor leading to foam cell formation[8]. ROS can acti-
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vate formation of AGE [9], polyol pathway [10], hex-
osamine pathway and PKC [11], involved in the
pathogenesis of vascular complications [12]. Superoxide
is dismutated to H2O2 by MnSOD in the mitochondria
and by CuZnSOD in the cytosol [13]. H2O2 is converted
to H2O and O2 by glutathione peroxidase or catalase in
the mitochondria and the lysosomes [14].
We still have to elucidate the fact that some patients with
DM develope vascular complications but this cannot be
seen in the others with the same level of disease control
[15]. We have focused on the genes encoding superoxide
dismutases and catalase. Specifically, we have focused on
SNPs for their likely functional role: SOD1 +35A/C (ref-
SNP ID: rs2234694) which is located adjacent to the
splice site (exon3/intron3 boundary), SOD2 Ala16Val
(refSNP ID: rs4880) which has been suggested to alter
protein structure [16] and function (C/T substitution in
exon 2, codon position 2, aminoacid position 16) and cat-
alase -21A/T (refSNP ID: rs7943316) which is located
inside the promotor region just proximal to the start site.
CuZnSOD also called SOD1, EC 1.15.1.1 is one of the cel-
lular defense systems for oxidative insults [17]. The
increase of CuZnSOD expression in human smooth mus-
cle cells protects against oxidative injury. OxLDL caused
an increase in the DNA binding activity of activator pro-
tein-1 and nuclear factor ?B, which is inhibited by CuZn-
SOD overexpression. MnSOD also called SOD2, EC
1.15.1.1 is present in the mitochondria. C/T substitution
(GCT/GTT) has been shown to change the structural con-
formation of the mitochondrial targeting sequence (MTS)
of the enzyme. Associations have been found between the
Ala16Val SNP and neurodegenerative disorders [18]. CAT,
EC 1.11.1.6 is present in the peroxisomes and exists as a
dumbbell-shaped tetramer of four identical subunits. Sev-
eral SNPs in the CAT gene have been reported, most of
these are associated with acatalasaemia [19].
Methods
Subjects
Total of 120 T1DM, 306 T2DM and control group of 140
healthy subjects without family history of diabetes were
examined in this study. Diagnosis of T1DM and T2DM
was based on WHO/ADA definition of diabetes (1999),
healthy subjects don't meet the criteria for the diagnosis of
DM. They were in good health and namely free of any
comorbidities often associated with DM, especially with
T2DM (arterial hypertension, obesity, hyperlipoprotein-
aemia) and other endocrine disorders. Microangiopathy
was confirmed by ophthalmoscopy or by the presence of
peripheral neuropathy (diagnosis was based on clinical
features and by physical examination using 10 g monofil-
ament, tuning fork and biothesiometry) in 167 patients
who did not have any evidence of macrovascular disease
from the clinical picture (no history of angina pectoris,
normal ECG records or normal coronarography). Patients
were excluded from this group in the case of suspection on
autonomic neuropathy made from physical examination
(tachycardia recorded by ECG in the resting state, systolic
blood pressure reaction on orthostatism). 66 subjects had
macrovascular complications manifested by ischaemic
heart disease (diagnosis was based on ECG or coronarog-
raphy), ischemic disease of the lower limbs (diagnosis
was based on angiography of lower limbs arteries) or had
history of stroke (diagnosis was based on clinical features
and computer tomography). The remaining 161 diabetic
patients were free of any complications. Clinical and lab-
oratory characteristics are shown in Tab. 1. The research
has been carried out within the ethical framework,
informed consents of all participants are documented.
Table 1: Clinical and laboratory characteristics.
T1DM P values (a) T2DM Controls P values (b)
Gender (males/females) 58/62 0,602 156/150 93/87 0,198
Mean age (years) 40 ± 12 0,022 57 ± 15 39 ± 9 0,043
Duration of DM (years) 18 ± 9 0,853 17 ± 8 0 -
BMI (kg/m2) 22 ± 4 0,03 30 ± 5 21 ± 5 0,027
Systolic BP (mmHg) 120 ± 10 0,748 125 ± 25 120 ± 20 0,676
Diastolic BP (mmHg) 60 ± 20 0,521 70 ± 30 70 ± 15 0,621
Microvascular complications(n) 40 0,048 159 0 -
Macrovascular complications(n) 14 0,016 52 0 -
FPG (mmol/l) 6,60 ± 1,35 0,058 7,82 ± 2,29 4,95 ± 0,76 0,009
HbA1c (%) 6,1 ± 1,9 0,321 6,7 ± 1,8 0 -
GFR (MDRD) (ml/s/1,73 m 2) 1,23 ± 0,35 0,179 1,09 ± 0,28 1,35 ± 0,22 0,041
Total cholesterol (mmol/l) 4,8 ± 0,5 0,042 5,3 ± 0,7 4,8 ± 0,3 0,205
HDL-C (mmol/l) 1,55 ± 0,35 0,216 1,31 ± 0,32 1,75 ± 0,66 0,325
LDL-C (mmol/l) 3,22 ± 0,53 0,116 3,57 ± 0,81 3,10 ± 0,74 0,234
Triglycerides (mmol/l) 1,31 ± 0,30 0,031 1,99 ± 0,79 1,23 ± 0,48 0,038BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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Laboratory measurements
Venous blood samples were drawn after an overnight fast-
ing. Plasma (Li-Heparine) glucose, creatinine were meas-
ured in central biochemistry laboratory. Serum total
cholesterol, HDL-cholesterol and triglycerides (TG) were
measured by automated enzymatic methods on Hitachi
analyzer, LDL cholestrol was calculated according to
Friedewald formula. HbA1c was measured by high-per-
formance liquid chromatography. Superoxide dismutase
activity was determined spectrophotometrically by xan-
thine/xanthine oxidase system by Genesys 5 spectropho-
tometer, USA. The method is based on the reaction
described by McCord and Fridovich [20]. SOD activity
was expressed in international units (U).
DNA analysis
Blood was extracted from the peripheral blood (5–10 ml)
and genomic DNA was prepared from leucocytes (mini-
mal amount of leucocytes was 3,5. 109 /l) by sodium
dodecylsulphate (SDS) lysis by ammonium acetate extrac-
tion and ethanol precipitation. Determination of the SOD
and CAT polymorphisms was achieved by PCR-RFLP anal-
ysis. Details are shown in Tab. 2. Digested PCR products
were visualised by UV transillumination following ethid-
ium bromide staining and migration compared against
DNA ladder and a positive RFLP control sample. 3% aga-
rose gel including 0,5 µg/ml ethidium bromide, 10 µl of
molecular markers (two different types used simultane-
ously) and 20 µl of amplicon for the other wells were
applied for electrophoresis. 0,5 × TBE buffer (pH 8)
including 0,5 µl/ml ethidium bromide was used. Running
conditions were 100 V, 40 mA and 140 min. Informations
about all SNPs and SNP ID were obtained from the NCBI
homepage and all SNPs have been validated by multiple,
independent submissions to the refSNP cluster. The geno-
typing success rate was 95.0% (range 91.1 to 98.4%).
Water control, internal controls and previously genotyped
samples were included in each plate to ensure accuracy of
genotyping. Positive and negative controls were used in
each genotyping assay. To ensure quality control, the gen-
otyping analysis was performed "blind" with respect to
case/control status. About 10% of the samples were ran-
domly selected to be genotyped again by a different inves-
tigator, who was also unaware of the status of studied
subjects.The results were concordant. The polymorphisms
were also examined by PCR and RFLP analysis described
previously [21-23].
Statistical analysis
Age, BMI and duration of diabetes were compared
between studied groups using Student's t-test. Statistical
analyses of frequency counts were performed using the
Chi-square (?2) test. Comparison of continuous variables
(HbA1c) among the SOD genotypes was performed with
the use of analysis of variance (ANOVA). A logistic regres-
sion analysis was performed to evaluate the interaction
between the genotypes and other variables in relation to
the prevalence of macro- or microangiopathy. In this anal-
ysis, the dependent variable was the presence or absence
of vascular complication. Independent variables included
in this analysis were BMI, age, present HbA1c level, type of
diabetes, duration of diabetes, SOD activity and genotype.
P values < 0.05 were considered as significant. The labora-
tory data are expressed as means ± SD. The analysis was
performed using programme Statistica 6.0 (StatSoft). Test-
ing for deviation from Hardy-Weinberg equilibrium
(HWE) was performed and all the observed genotype fre-
quencies were in agreement with HWE.
Results
SOD activity
Serum SOD activity was significantly decreased in T1DM
(0,75 ± 0,18 U; 95% CI: 0,72, 0,79) and in T2DM patients
(0,71 ± 0,33; 95% CI: 0,67, 0,74) compared to the control
subjects (1,67 ± 0,33, 95% CI: 1,61, 1,72), both p < 0,01.
Differences between T1DM and T2DM in SOD activity
were not found statistically significant (p = 0,14). No gen-
der or age influence on its activity was found in diabetic
patients or healthy subjects. Difference in SOD activity
between diabetic patients and healthy subjects is probably
accountable not only by genotype background but also by
various effects in terms of diabetes, e.g. enzyme glyca-
tion.The lower serum SOD activity was found in patients
(T1DM and T2DM) with macrovascular complications
Table 2: Sequences of used primers and used restrictases.
SNP sequence of used primers restriction endonuclease restriction fragments
SOD1 35 A/C 5'CTATCCAGAAAACACGGTGGGCC 3' HhaI C allele 71 bp and 207 bp
A allele 278 bp
5'TCTATATTCAATCAAATGCTACAAAAC3'
SOD2 A16V (C/T) 5'GCTGTGCTTTCTCGTCTTCAG 3' BsaWI C allele 267 bp
T allele 183 bp and 84 bp
5'TGGTACTTCTCCTCGGTGACG3'
CAT -21 A/T 5'-AATCAGAAGGCAGTCCTCCC-3' HinfI A allele 203 bp and 47 bp
T allele 250 bp
5'-TCGGGGAGCACAGAGTGTAC-3'BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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(0,51 ± 0,31 U; 95%CI: 0,43, 0,58) than in those with
microvascular complications (0,74 ± 0,16 U; 95%CI:
0,71, 0,76), p < 0,01 or without any vascular complica-
tions (0,76 ± 0,34 U;95%CI: 0,71, 0,81), p < 0,05.
The effect of the SOD1 +35A/C polymorphism on SOD 
activity in healthy subjects and diabetic patients with DM
The AA genotype was the most common observed in the
healthy subjects followed by the AC genotype, whereas
the AC was more common than the AA genotype in T1DM
and T2DM patients (Tab. 3). Significant differences
between the allele and genotype frequencies for the SOD1
+35A/C polymorphism was observed in T1DM as com-
pared to controls (A: 0.69 vs 0.52, p < 0.01; C: 0.31 vs.
0.48, p < 0.05) and similarly in T2DM (A: 0.58 vs. 0.52; C:
0.42 vs 0.48, p < 0.05). This SNP was related to SOD
serum activity. Higher activities were found in AA than in
CC genotypes of diabetic patients (Tab. 3). Statistical
analysis (analysis of variance) showed significant trend
towards possible association of AA genotype with higher
activity (P (trend) = 0.029). Diabetic and healthy subjects
have been pooled together as one group in the study of
association between SOD activity and genotypes to
improve statistical power of analysis. Differences among
these subjects in age, duration of diabetes, presence of
other co-morbidities were included.
Relationship between the SOD2 Ala16Val (C/T) 
polymorphism and SOD activity in healthy subjects and 
patients with DM
The TT genotype (Val/Val) was the most common in both
T1DM and T2DM patients, CT genotype was the most
common in healthy subjects whereas the CC genotype
(Ala/Ala) was the rarest one in all groups (Tab. 3). The
allele frequency of the SOD2 polymorphisms was signifi-
cantly different in healthy persons compared to T1DM
and T2DM patients (T allele (Val): 0.54 (controls) vs. 0.81
(T1) or 0.85 (T2), p < 0.05 and C allele (Ala): 0.46 (con-
trols) vs. 0.19 (T1) or 0.15 (T2), p < 0.05 (Fig. 1). In all
groups of diabetic patients SOD activity was the highest in
the CC genotype (Ala/Ala) and the lowest in the TT geno-
type (Val/Val) (Tab. 3.).
CAT polymorphism in diabetes mellitus
We found no statistically significant differences between
frequencies in alleles of CAT SNP between diabetic
patients and healthy subjects (p = 0,294) (Tab. 3). Control
of diabetes was not influenced by polymorphisms in the
CAT gene (Tab. 4).
The association of enzyme activity and polymorphisms in 
SOD1 and SOD2 with diabetes control and vascular 
complications of diabetes mellitus
Diabetes control expressed by glycated haemoglobin val-
ues was poorer in TT genotype (Val/Val) of SOD2 (7,10 ±
1,51; 95%CI: 6,42–7,91 in T1DM and 7,29 ± 1,49;
95%CI: 6,70–8,46 in T2DM) than in CC genotype (Ala/
Ala) of SOD2 (6,39 ± 1,1; 95%CI: 5,7–7,0 in T1DM and
6,71 ± 1,21; 95%CI: 5,73–6,99 in T2DM), p < 0,05.
No effect of SNP in SOD1 gene on diabetes control was
found. Glycated haemoglobin was 6,7 ± 1,4; 95%CI:
5,41–6,23 in T1DM and 6,9 ± 1,4; 95%CI: 5,48–6,09 in
T2DM, both in AA genotype of SOD1 gene and 6,59 ±
1,22, 95%CI: 5,08–6,24 in T1DM and 6,61 ± 1,51;
95%CI: 5,02–6,05 in T2DM, both in CC genotype of
SOD1 gene, with p = 0,124.
Similar findings were made in CAT gene. Glycated haemo-
globin was 6,14 ± 1,11; 95% CI: 6,06–6,57 in T1DM and
6,50 ± 0,85; 95%CI: 6,32–7,25 in T2DM, both in AA gen-
otype of CAT and 6,19 ± 1,32, 95% CI: 6,09–6,60 in
T1DM and 6,61 ± 0,54; 95%CI: 6,45–7,05 in T2DM, both
in TT genotype of CAT gene, with p = 0,249.
Significantly different genotype frequencies of SNPs were
found in diabetic patiens (T1DM and T2DM) with mac-
roangiopathy (MA+) in SOD1 and SOD2 genes. When
compared these with CC genotype vs. AC and AA geno-
types of SOD1: OR (odds ratio) was 1.73; 95% CI 1.45–
5.37 with p < 0,05, CC genotype (Ala/Ala) vs. CT (Ala/
Val) and TT (Val/Val) genotypes of SOD2: OR was 0,62;
95%CI 0,58–0,90 with p < 0,01. When compared AA gen-
otype vs. AT and TT genotypes of CAT: OR was 1.05;
95%CI 0,78–1,13, p = 0,851.
Table 3: SOD activities according to genotype, genotypes frequencies.
AA AC CC TT (Val/Val) CT (Ala/Val) CC (Ala/Ala) AA AT TT
T1DM n (%) 58 (48) 50 (42) 12 (10) 79 (66) 36 (30) 5 (4) 48(40) 53 (44) 19(16)
SOD act (U) 0,76 ± 0,15 0,74 ± 0,13 0,73 ± 0,19 0,73 ± 0,14 0,74 ± 0,23 0,77 ± 0,18
T2DM n (%) 104 (34) 147(48) 55 (18) 220 (72) 80 (26) 6 (2) 110 (36) 147 (48) 49 (16)
SOD act (U) 0,73 ± 0,29 0,72 ± 0,36 0,70 ± 0,31 0,72 ± 0,28 0,72 ± 0,19 0,75 ± 0,15
Controls n (%) 49 (27) 90 (50) 41 (23) 52 (29) 90 (50) 38 (21) 67 (37) 86 (48) 27 (15)
SOD act (U) 1,66 ± 0,31 1,67 ± 0,35 1,66 ± 0,28 1,58 ± 0,28 1,60 ± 0,35 1,63 ± 0,08
The occurrence of genotypes in studied polymorphisms among T1, T2 diabetic patiens and healthy subjects (controls), serum superoxide dismutase 
activity separated according to the genotypes in compared groups (AA/AC/CC in SOD1 gene, TT/CT/CC in SOD2 gene, AA/AT/TT in CAT gene). Data 
are expressed in mean ± SD, n means number of cases, brackets mean genotype frequencies (allele frequencies and differences among them are 
mentioned in text), SOD act means enzyme activity.BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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Macroangiopathy was associated with significantly higher
frequency of C allele in SOD1 gene (0,58 in MA group vs.
0,42 in DM group without complications, p < 0,01), lower
frequency of C alelle (Ala) in SOD2 gene (0,28 in MA
group vs. 0,39 in DM group without vascular complica-
tions, p < 0,05) whereas no such distribution was found
in CAT gene, p = 0,594.
No differences in genotype frequencies were associated
with microangiopathy (MI+). When compared these with
CC genotype vs. AC and AA genotypes in SOD1: OR was
0,91; 95%CI 0.74–1.32 with p = 0.783, CC genotype (Ala/
Ala) vs. CT (Ala/Val) and TT (Val/Val) genotypes in SOD2:
OR was 0,96; 95% CI 0.52–1.38 with p = 0.852 and AA
genotype vs. AT and TT genotypes in CAT: OR 1,04 95%;
CI 0,37–1,26 with p = 0,814. No statistically significant
differences in allele frequencies were found in all SNPs of
the studied genes in the patients with microangiopathy
when compared with patients without vascular complica-
tions (C allele in SOD1 was 0,47 in MI group vs. 0,42 in
DM group without complications, p = 0,118, T allele in
SOD2 was 0,35 in MI group vs. 0,39 in DM group without
complications, p = 0,242). Frequencies of genotypes
ranged according to presence of vascular complications in
both types of diabetes mellitus are showed in Fig. 1.
Genotype frequencies according to presence of vascular complications Figure 1
Genotype frequencies according to presence of vascular complications. Distribution of genotypes in SOD1 (A/C 
allele) and SOD2 (C/T allele, Ala/Val) in both types of diabetes mellitus according to presence of macroangiopathy (MA+) or 
microangiopathy (MI+) or no complications (MA-MI-). Explanation of results is mentioned in the text.
Table 4: Genotype frequencies in CAT gene according to 
presence of vascular complications and values of glycated 
haemoglobin according to the genotype.
Genotype MA+ MI+ MA-MI- HbA1c
AA 0,28 0,32 0,34 6,28 ± 1,25
AT 0,50 0,49 0,49 6,35 ± 1,10
TT 0,22 0,19 0,17 6,32 ± 1,22
Genotype frequencies of CAT gene according to the presence of 
vascular complications in patients with diabetes mellitus. MA+ means 
presence of macroangiopathy, MI+ means presence of 
microangiopathy, MA-MI- group involves patients without vascular 
complications. HbA1c is glycated haemoglobin (%) marked as mean ± 
SD.BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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We found negative correlation between serum superoxide
dismutase activity (SOD) in both types of diabetes melli-
tus and the values of glycated haemoglobin (HbA1c %)
(Fig. 2), as well as the presence of vascular complications
in both types of diabetes (Fig.3).
Association of the SOD1, SOD2 and CAT polymorphism,
BMI, age, duration of diabetes, sex, type of diabetes and
SOD activity as independent variables with the presence
of microangiopathy or macroangiopathy as dependent
variables was performed using a logistic regression model.
This analysis indicated that SOD1 and SOD2 genotypes
are significantly associated with macroangiopathy.
Another variables significantly associated (p < 0,05) with
angiopathy were HbA1c, SOD activity and duration of
diabetes. No independent contribution has been demon-
strated for age, sex, BMI and the type of diabetes. (Tab. 5).
Discussion
Our findings in SOD2 gene are in agreement with previ-
ous observations of other authors [24]. We also confirmed
known fact that serum SOD activity is significantly
reduced in patients with DM [25]. The presence of TT
(Val/Val) genotype in SOD2 gene was associated with
poorer diabetes control in comparison with CT (Ala/Val)
and CC (Ala/Ala) genotypes. Macroangiopathy was asso-
ciated with significantly lower frequency of C (Ala) alelle
of Ala16Val SNP of SOD2 gene. This has not been con-
firmed by another study focused on the role of antioxida-
tive enzymes (including SOD2) in determining genetic
susceptibility to the coronary artery disease in patients
with T2DM [26]. Other studies suggest that Ala16Val SNP
of SOD2 gene is not related to pathogenesis of diabetes
but is associated with microangiopathy expressed as
microalbuminuria [27] or macular edema in patients with
Correlation between SOD activity and glycated haemoglobin Figure 2
Correlation between SOD activity and glycated haemoglobin. Data correlation between the values of glycated hae-
moglobin (HbA1c %) and serum superoxide dismutase activity (SOD) in both types of diabetes mellitus. The correlation coefi-
cients (Spearman) are r1 = -0,41 (T1DM), r2 = -0,23 (T2DM) with p < 0,05. Dotted lines mean 95% confidence intervals.BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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T2DM [28]. No such distrubution was found in microan-
giopathy in our study. Finally, we found negative correla-
tion between SOD activity in both types of diabetes and
level of control (expressed by glycated haemoglobin) and
presence of microangiopathy or macroangiopathy.
SNP in the signal sequence of SOD2 (Ala16Val) appears
to be a minor determinant of carotid atherosclerosis [19].
The Ala type of SOD2 might have an common alfa-helical
structure while the Val type might change its conforma-
tion to beta-sheet [29]. The Val variant of the SOD2 might
be present at a lower concentration in the mitochondria.
The processing study of these 2 leader signals has sug-
gested that the basal level of the SOD2 activity might be
the highest for Ala/Ala genotype (C/C) [29]. Observed
positive association of macroangiopathy and high levels
of glycated haemoglobin with the SOD2-Val/Val geno-
type could be explained, at least in part, by the Val izo-
form of the SOD2. It may lead to decrease resistance
against ROS produced in the mitochondria and to oxida-
tive damage of proteins[30]. The Ala allele of the SOD2
gene is more widespread than the Val allele in Caucasian
population in contrast to Asian populations.
Our results are indicative of potential effect of A/C SNP in
SOD1 gene on enzyme activity. It is known that deficiency
in SOD1 results in increased levels of vascular superoxide
and peroxynitrite and impaired endothelium-dependent
relaxation in both large arteries and microvessels [31] and
caused hypertrophy of arteries [32]. Macroangiopathy was
associated with significantly higher frequency of C allele
Correlation between presence of vascular complications and SOD activity Figure 3
Correlation between presence of vascular complications and SOD activity. Cross-correlation between the presence 
of vascular complications in diabetic patients and the level of serum superoxide dismutase activity. The correlation coeficients 
(Spearman) are r1 = -0,29 (T1DM), r2 = -0,28 (T2DM) with p < 0,05. Dotted lines mean 95% confidence intervals.BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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of +35 A/C SNP of SOD1 gene whereas no such distrubu-
tion was found in microangiopathy.
We found no statistically significant differences in distri-
bution of CAT alleles in studied SNP and no impact of this
SNP on the presence of vascular complications and the
level of glycated haemoglobin. Hypocatalasaemic patients
were found to have higher plasma levels of homocysteine
and lower levels of folate [19], suggesting these patients
are at greater risk for cardiovascular diseases. SNPs in the
catalase promoter have been identified in a Swedish pop-
ulation [33] but their relationship to the vascular disease
risk has not been determined. A variant within the catalase
promoter region has been associated with essential arte-
rial hypertension in an isolated Chinese population [34].
T1DM susceptibility locus on the chromosome 11p13
near to the catalase gene supports the idea of CAT gene
may play a role in DM [35]. On the other side another
authors found no evidence for a major effect of CAT SNPs
on T1DM susceptibility in two large sample collections
[36].
The study inconsistency in the association between geno-
types and DM or cardiovascular disease is partly due to
limits of conventional cross-sectional and retrospective
case-control studies because selection bias have to be con-
sidered and the statistical analysis might have failed to
demonstrate any significant differences. Large differences
among ethnic populations are known in the distribution
of genotypes which could be the reason for differences in
studies.
Conclusion
The presented findings show that the genotype distribu-
tion of the SOD1 and SOD2 in patients with diabetes mel-
litus can differed from nondiabetic individuals. We are
conscious of the limitation of this study with relatively
small sample size in comparison with wide epidemiolog-
ical studies, especially by providing subgroup analysis
within the group with diabetes mellitus. Nevertheless the
results of small studies with similar conclusions may
spark off suquent research. Genetic background may be at
least partly associated with disease control of diabetes and
consequently enzyme activities protecting against oxida-
tive stress. Vascular disorders like atherosclerosis are then
the results of combined genetic and metabolic changes.
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Variable p (MA) OR; 95%CI (MA) p (MI) OR; 95%CI (MI)
SOD1 35 A/C 0,048 1,73; 1,45–5,37 0,783 0,91; 0,74–1,32
SOD2 A16V 0,009 0,62; 0,58–0,90 0,852 0,96; 0.52–1.38
CAT -21 A/T 0,851 1,05; 0,78–1,13 0,814 1,04; 0,37–1,26
SOD activity 0,040 0,48; 0,20–5,9 0,048 0,62; 0,44–0,91
Present HbA1c 0,039 1,28; 1,12–1,87 0,041 1,26; 1,12–1,81
BMI 0,686 0,97; 0,90–1,11 0,852 0,98; 0,87–1,04
Duration of diabetes 0,038 1,96; 1,38–3,27 0,038 2,01; 1,50–4,31
Sex 0,86 0,97; 0,89–1,22 0,80 0,95; 0,88–1,15
Age 0,124 0,73; 0,49–1,54 0,152 0,81; 0,52–1,28
Type of diabetes 0,084 0,96; 0,89–1,65 0,079 0,88; 0,73–1,17
MA in brackets means presence of macroangiopathy, MI in brackets means presence of microangiopathy, OR means odds ratio, 95%CI means 
confidence interval (? = 0,05). MA and MI are dependent variables. Genotype (SOD1, SOD2, CAT), SOD activity, HbA1c, duration of diabetes, BMI, 
sex, age and type of diabetes act as independent variables. Variables significantly asssociated with macroangiopathy or microangiopathy are marked 
in table as bold.BMC Medical Genetics 2008, 9:30 http://www.biomedcentral.com/1471-2350/9/30
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